"Not as good as TALEN," was Cellectis's verdict on CRISPR gene editing, and it appears Pfizer concurs. The big pharma has licensed Cellectis's lead TALEN (not CRISPR) gene-edited CAR-T product candidate UCART19. Servier held an option on the rights, but exercised it early and handed it straight over to Pfizer.
Pfizer Picks 'Off-The-Shelf' CAR-T And Backs TALEN Over CRISPR
"Not as good as TALEN," was Cellectis's verdict on CRISPR gene editing, and it appears Pfizer concurs. The big pharma has licensed Cellectis's lead TALEN (not CRISPR) gene-edited CAR-T product candidate UCART19. Servier held an option on the rights, but exercised it early and handed it straight over to Pfizer.
More from Business
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.